Across TCGA pan-cancer cohorts, MIR520A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR520A data layer compared with 5 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MIR520A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR520A expression acts as an unfavorable survival marker.
LUAD and SARC are the cancer types where MIR520A Mutation most reproducibly stratifies survival.